8-K: Cargo Therapeutics Amends License Agreement with Oxford Biomedica, Modifying Royalty Structure

Cargo Therapeutics has amended its license and supply agreement with Oxford Biomedica, altering royalty payments and milestone structures for its lentiviral vector technology.

Summary

• Cargo Therapeutics has modified its agreement with Oxford Biomedica regarding lentiviral vectors used in their T-cell therapies.
• The amended agreement changes the royalty structure, eliminating royalties on CRG-022 and setting low single-digit royalties on other licensed products manufactured by Oxford Biomedica.
• Royalties will also apply to products manufactured by Cargo or a third party after a technology transfer.
• Cargo will pay up to $1.0 million in regulatory milestones for each target, except for CRG-022, which has a reduced milestone.
• A reduced commercial milestone for CRG-022 has also been agreed upon.

Sentiment

Score: 7

Explanation: The document indicates a positive adjustment to a key agreement, which is generally favorable. The elimination of royalties on CRG-022 is a positive, but the ongoing royalty and milestone obligations temper the overall sentiment.

Positives

• The elimination of royalties on CRG-022 for vectors manufactured by Oxford Biomedica reduces costs for that specific product.
• The amended agreement provides clarity on royalty obligations for products manufactured by Cargo or a third party after technology transfer.
• The reduced commercial milestone for CRG-022 could lower overall costs associated with that product.

Negatives

• Cargo will still owe low single-digit royalties on net sales of licensed products other than CRG-022 manufactured by Oxford Biomedica.
• Regulatory milestones of up to $1.0 million per target will be paid, which could be a significant expense.

Risks

• The company is still reliant on Oxford Biomedica for the supply of lentiviral vectors.
• The company will need to manage the technology transfer process effectively to avoid delays and additional costs.
• The company will need to achieve regulatory milestones to avoid additional costs.

Future Outlook

The amended agreement is expected to impact the company's cost structure and royalty obligations for its T-cell therapies.

Management Comments

• The foregoing description of the Amended Agreement is not complete and is qualified in its entirety by reference to the Amended Agreement.

Industry Context

This agreement is relevant to the cell and gene therapy industry, where licensing and supply agreements for key components like lentiviral vectors are common. The modification of royalty structures is a typical negotiation point in such agreements.

Comparison to Industry Standards

• Many biotech companies rely on contract manufacturing organizations (CMOs) like Oxford Biomedica for vector production, similar to Cargo Therapeutics.
• Royalty rates in the low single-digit percentages are common in biotech licensing agreements, but can vary based on the stage of development and exclusivity.
• Milestone payments are a standard part of biotech agreements, often tied to regulatory approvals and commercial success.
• Companies like bluebird bio and Novartis have similar agreements for their cell and gene therapies, with varying royalty and milestone structures.

Stakeholder Impact

• Shareholders may view the amended agreement positively due to the potential for reduced costs and improved financial outlook.
• The agreement impacts the company's relationship with Oxford Biomedica, a key supplier.

Next Steps

• The amended agreement will be filed as an exhibit to the company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.

Key Dates

Keywords

Lentiviral Vectors, T-cell Therapy, License Agreement, Royalties, Milestones, Oxford Biomedica, CRG-022, Technology Transfer